1st Order Pharmaceuticals Inc: 1OP-2198

[DebInAustralia]

They are testing this drug for a severe form of childhood epilepsy, that's why it's tested on pediatric patients.

I skimmed through thread. Has the phase 3 trial begun?

How long will this trial take?

Has this drug been tested for tinnitus?

Will this drug be available off label for tinnitus?

 

[Autumnly]

Has the phase 3 trial begun?

XEN-496

• Phase III trial is supposed to start before the end of 2020
• Kv7 potassium channel modulator, is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of epilepsy

XEN1101

• currently in Phase 2b "X-TOLE", topline data is anticipated in the first half of 2021
• Novel, Next‐Generation KCNQ2 Modulator for the Treatment of Epilepsy
• improved version of ezogabine; might help with tinnitus since some patients reported benefit from using ezogabine but "there is very limited clinical data and yet no evidence in humans for an effect of Kv7 channel modulation on tinnitus" source
• Other potential indications for XEN1101 include tinnitus and ALS. source

Ezogabine/retigabine

Spoiler

• ezogabine/retigabine - Trade Name: Trobalt/Potiga
• "One of the more effective, called retigabine, helps open KCNQ potassium channels, the "brakes" that shut down the signaling of overly excited nerves. Unfortunately, retigabine has awful side effects. Because of this, it's usually only given to adults who don't get relief from other epilepsy drugs."
• "There are five different kinds of KCNQ potassium channels in the body, but only two are important in epilepsy and tinnitus: KCNQ2 and KCNQ3. The problem with retigabine is that it acts on other KCNQ potassium channels as well. That's why it has so many unwanted side effects." source
  
• Thanos Tzounopoulos from the University of Pittsburgh is also working on an improved version of retigabine but it's still pre-clinical

Has this drug been tested for tinnitus?

XEN1101 and XEN496 haven't been tested for tinnitus but potassium channels might be a target for pharmacological treatments for tinnitus:

• Potassium channels as promising new targets for pharmacologic treatment of tinnitus

 

[Greg Sacramento]

@Autumnly @Paulmanlike

Xenon - has positive following by medical analysts on some stock and hedge boards.
Xenon may turn out to be a good investment.
VistaGen has competition from SAGE.

Biogen, Sage Therapeutics enter $1.5 bln deal to develop, sell neurological treatments | Nasdaq